Nephroapp
Exam Cases MCQ Bank

Search

Find tools, topics, and resources

Welcome to Nephroapp
Sign in to keep your progress and bookmarks.
Log in Create account
Explore
Exam cases MCQ Bank Topics Plans and pricing
App
Explore NephroApp
Exam Cases MCQ Bank

Study

Exam cases
MCQ Bank
Fast Recaps
Plans and pricing
‹ Exam Cases
CRRT Prescription (Septic ICU)
Case map
Fast Recap Case scenarios Viva Q&A Spoken approach Escalation ladder Management Quick reference Red flags Flowchart Exam traps & pitfalls Differential Examiner keywords Investigations & data Guideline algorithm Recent changes Immediate priorities Why it happens
Exam tools
Study
📋Topics 🎯By branch
🎯 NephroApp · Exam Cases
CRRT Prescription (Septic ICU)
nephroapp.com
🔥 #4 most asked · 23 sittings · 42× CRRT / ICU SCFHS Consultant Viva Filtration Fraction

CRRT Prescription (Septic ICU)

By Dr. Hossam Abohassan · Updated Nov 8, 2026

CRRT prescription is the classic ICU viva: a ~100 kg septic, anuric patient with hyperkalemia and severe acidosis on inotropes. The examiner wants a complete written order (access, modality, dose in mL/kg/h, blood flow, dialysate/replacement split, anticoagulation, monitoring) and then attacks with the filtration fraction equation when the filter clots, and asks the trial names (RENAL, ATN, STARRT-AKI). Keywords: CVVHDF, 25-30 mL/kg/h, FF = UF rate / plasma flow, keep FF <20-25%.

Practise 32 MCQs on this topicExam-style questions with explanations →

Watch & listen to this topic

🎬 Full video · the whole approach, animated

Open on YouTube ↗

⚡ NephroApp short · 2 min summary

Your browser does not support audio playback.

🎧 Full podcast

Your browser does not support audio playback.

⚡ NephroApp short · 2 min summary

Your browser does not support audio playback.

🎧 Full podcast

Your browser does not support audio playback.
Exam links & past questions
📌 Exam topic #4 · CRRT prescription (septic ICU, dose, modes) 23 sittings · 42×
Also on this exam topic: DrillCRRT Alarms, Citrate and Troubleshooting Scenarios TopicCRRT Effluent Dose in the ICU: KDIGO 20-25 mL/kg/h, RENAL and ATN TopicWriting a CRRT Order: Modality, Fluids, Citrate and Alarm Troubleshooting TopicCRRT versus SLED in the Unstable ICU Patient
⚖️ Comparison tables: CRRT vs SLED vs IHD SCUF vs CVVH vs CVVHD vs CVVHDF CRRT anticoagulation: Citrate vs Heparin vs None Standard vs high-dose CRRT effluent RRT timing trials: STARRT-AKI, AKIKI, IDEAL-ICU, AKIKI 2 CRRT replacement fluid: pre- vs post-dilution
🎯 Asked in the real exam · 32 reports — answer each aloud
  1. ICU patient, 100 kg, severe acidosis and K 6.5, referred for dialysis: write the CRRT prescription.Oct 2026
  2. Fluid-overloaded patient with K 7 referred from urology: write the CRRT prescription now.Oct 2026
  3. CRRT prescription.Oct 2026
  4. ICU consult for patient with edema: assess comorbidities, cause of admission, vitals; differentiate cardiogenic vs septic shock and managing the renal aspect (AKI workup); priority = full-dose antibiotics from source controlMar 2026
  5. 100 kg ICU patient with ventilator-acquired pneumonia, on hemodynamic support, hyperkalemia/anuria/creat 560 - CRRT indicated, give type and dose.Nov 2025
  6. Hypotensive patient with septic shock: order of CRRT and how to calculate; difference between UF and HF; modes of CRRT.May 2025
  7. CRRT dose in AKI patient 100 kg, CVP 25; nurse calls because filtration fraction is 35 - what to do.Apr 2025
  8. 80 yr old male in ICU with multiorgan failure and septic shock, weight 100 kg — write full CRRT prescription.Apr 2025
  9. Session 2 recall: ICU patient with septic shock (pneumonia), 100 kg, present AKI, K 7.6 — CRRT prescription; PD peritonitis DDx/management/catheter removal; hyponatremia Na 100/122 with SIADH investigations and management; persistent HTN secondary workup; MN biopsy management and follow-up.Apr 2025
  10. CCU patient (100 kg) with heart failure, ATN, hyperkalemia, acidosis, oliguria — CRRT prescription (dose 25-30 mL/kg/hr, dialysate/blood flow); nurse reports clotting and filtration fraction >20% — reduce FF (increase blood pump, pre-filter replacement, reduce net ultrafiltration)Mar 2025
  11. CRRT: prescription, anticoagulation method, and the filtration fraction equation.Dec 2024
  12. CRRT: name the major studies done on CRRT/dialysis modalities in renal patients and their outcomes; when to escalate prescription.Dec 2024
  13. S2Q7: ICU septic shock, 100 kg — CRRT CVVHDF prescription and anticoagulation. (Q6 was a trap about '20yo hematuria, diagnosis RTS/renal tubular striction' which candidate said does not exist.)May 2024
  14. 70M pneumonia, sepsis, AKI, BP 70/40 — CRRT prescription.Feb 2024
  15. 50 y/o septic shock on levophed, anuric, metabolic acidosis (pH 6.9): CRRT prescription.Jan 2024
  16. Hypotensive patient with septic shock: order CRRT and calculate dose; difference between UF and HF; modes of CRRT.Sep 2023
  17. Sepsis, fluid overload, acidosis in ICU: CRRT prescription.
  18. CRRT vs IRRT — when to choose each, types of dialysis in AKI, KDIGO recommendations on dose, CRRT modalities, anticoagulation, and LMWH
  19. CRRT anticoagulation (citrate, heparin, argatroban), CRRT complications, when to stop CRRT, and CRRT dose calculation (filtration fraction, blood/plasma flow formulas)
  20. CRRT prescription for a 100 kg patient; filtration fraction (FF) is 35% after 3 hours — what is your action?
  21. CRRT prescription looks; after 6 hours FF 40% — your management.
  22. Difference between CRRT and SLED
  23. CRRT prescription
  24. CRRT dose in the ICU
  25. CRRT prescription (detailed prescription and complication monitoring)
  26. AKI definition (KDIGO); prescription of CVVH/CVVHD; first ER investigation; obstructive AKI management
  27. CRRT dose for a 100kg patient - write an order as if for the nurse
  28. 70yo ICU with pneumonia/ARDS, hemodynamically unstable, Cr 660: approach to dialysis prescription
  29. 50yo ICU pneumonia, BP 85/46, given 3L NS + inotropes, Cr rose 80->187: evaluation and HD prescription
  30. Patient admitted to ICU for septic shock (pneumonia), weight 100kg, presents AKI with K 3.76 (sic): prescription of CRRT
  31. Woman 50yo, AKI, sepsis, hyperkalemia: prescription of CRRT (100kg weight); monitor K after 6h, K 7.4 mmol/l - management
  32. ICU patient in septic shock with hypotension and AKI: indications for CRRT and the prescription — what dose, why, and which study?
Fast Recap · 7 stops

CRRT prescription at a glance

100 kg, septic, anuric, K 7, on inotropes. Start now, run continuous, prescribe a deliverable dose, keep the filter alive.

  1. K 7 Indication Refractory K: start now, treat in parallel.
  2. Modality: CVVHDF Continuous for BP, diffusion for potassium.
  3. FF ! Circuit life Citrate first; filtration fraction when clotting.
1 Indications 2 Access & modality 3 Dose 4 Anticoagulation 5 Filtration fraction 6 Drugs & electrolytes 7 Discontinuation
  1. 1

    Stop 1 · Initiation

    Indications and timing of initiation

    Refractory K >6.0: start now. Acidosis alone: bicarbonate first.

    K 6.0 7 pH <7.20 HCO3
    1

    Potassium

    Therapy-resistant K >6.0: start immediately (ICU Rec 1.1).

    2

    Acidosis

    pH <7.20 alone: IV bicarbonate first, unless another urgent indication.

    3

    Volume or uraemia

    Refractory overload or uraemic complications (KDIGO 2012).

    Temporising therapy

    Calcium, insulin-dextrose, salbutamol while access is placed.

    Deferred initiation

    Deferred over early start (KDIGO 2026 draft, 1C); start for refractory complications.

    STARRT-AKI

    Death 43.9% vs 43.7%; more RRT dependence if accelerated.

    AKIKI

    No mortality difference; 49% of delayed never needed RRT.

    IDEAL-ICU

    Septic shock, 12 h vs 48 h: stopped for futility.

    BICARICU-2

    Bicarbonate to pH 7.30: mortality unchanged; less KRT (secondary).

    Memory hook

    “Refractory potassium starts the pump; acid alone gets the bicarbonate.” AKIKI 2: do not delay beyond standard triggers.

  2. 2

    Stop 2 · Set-up

    Vascular access and modality selection

    Right IJ, continuous, diffusive high dialysate flow: CVVHDF.

    R IJ CVVHDF
    Access · KDIGO 2012 Right IJ first
    Non-tunnelled dual-lumen, ultrasound-guided; chest film before use.
    Continuous vs intermittent Unstable → CRRT
    Instability, high inotropes, raised ICP, liver failure (KDIGO 2026 draft: CRRT or acute PD, 2C).
    IRRT: stable, rapid removal. SLED / PIRRT: acceptable if unstable.

    CRRT modalities

    UF only
    SCUF

    Water only; no effective solute clearance.

    Convection
    CVVH

    Small and middle molecules; needs replacement fluid.

    Diffusion
    CVVHD

    Small solutes; uses dialysate.

    Both
    CVVHDF

    Diffusion + convection: typical ICU choice.

    • Diffusion vs convection: similar outcomes; severe hyperkalaemia → high dialysate flow.
    • Pre-dilution: less clearance per litre (dose higher), less clotting.
    • Buffer: bicarbonate, not lactate, in shock or liver failure.
    Exam trap

    IHD on maximal inotropes. Hemodiafe 2006: no difference; ICRAKI 2026: IHD not noninferior, higher mortality.

  3. 3

    Stop 3 · Dose

    Dose prescription

    Prescribe 25–30 mL/kg/h to deliver 20–25 despite downtime.

    20–25 35–40 25–30 mL/kg/h prescribed
    Effluentthe dose= Dialysateflow+ Replacementflow+ Net UFfluid goal

    Dose = 24 h effluent ÷ weight ÷ 24. Actual weight; BMI ≥30: ideal or adjusted (KDIGO 2026 draft).

    Prescribe 25–30 mL/kg/h
    About 2,500–3,000 mL/h at 100 kg.
    Deliver 20–25 mL/kg/h
    ICU guideline, KDIGO 2012 and 2026 draft. No HVHF in sepsis.
    Blood flow QB 150–200 mL/min
    Clinical Handbook range 100–250 mL/min.
    Net UF Modest, individualised
    1.01–1.75 mL/kg/h appeared safe; >1.75 linked to mortality (observational).
    Worked example · account for downtime
    • 100 kg: 3,000 mL/h × 20 h = 60 L/day = 25 mL/kg/h delivered.
    • 75 kg: deliver 1,500–1,875 mL/h; prescribe ~2,250 mL/h.
    • Delivered dose low? Fix anticoagulation and circuit life first, then raise the rate.
    Memory hook
    25–30prescribe 20–25deliver 150–200QB ~3,000mL/h · 100 kg

    Slightly above target, no higher.

    Exam trap

    35–40 mL/kg/h as target. RENAL (40 vs 25): 90-day mortality 44.7% both. ATN: no benefit, more hypotension.

  4. 4

    Stop 4 · Anticoagulation

    Anticoagulation

    Regional citrate if no contraindication: longer filter life, fewer bleeds.

    citrate pre-filter Ca post-filter iCa <0.35 total:iCa 2.5

    Guideline recommendations

    KDIGO AKI 2012

    Suggests citrate over heparin (2B).

    ICU guideline 2026

    Citrate = heparin for outcomes; citrate if bleeding risk; UFH over LMWH.

    KDIGO 2026 draft

    Recommends citrate over heparin (1B); UFH, epoprostenol, nafamostat alternatives.

    Citrate set-up · mind the units Fixed to blood flow
    ACD-A mL/h ≈ 1.5 × QB in mL/min: QB 150 → 225 mL/h.
    Never 150% of QB in mL/h. Change citrate in proportion to QB.
    Citrate monitoring Two calcium targets
    Post-filter iCa <0.35 mmol/L; separate calcium to normal systemic iCa.
    iCa 4-hourly, then 6-hourly; total Ca ≥12-hourly; acid–base, lactate.

    Excess buffer

    Ratio <2.5 + alkalosis: review fluid buffer and citrate rate.

    Citrate accumulation

    Ratio >2.5, anion-gap acidosis, rising Ca need: treat hypocalcaemia, reduce citrate.

    Persists: stop citrate → bicarbonate CRRT, heparin or none.

    • Avoid citrate: progressive lactic acidosis + shock + severe liver failure. Either alone: monitor.
    • Other citrate issues: hypo/hypercalcaemia, hypernatraemia, hypomagnesaemia.
    • Heparin: trials 2,000–5,000 IU, then 7–10 IU/kg/h; Handbook 500–1,000 IU, then ~500 IU/h.
    • Heparin targets: aPTT q6h (RICH 45–60 s) or anti-Xa 0.3–0.6 IU/mL.
    • Acute HIT: argatroban (bivalirudin, danaparoid); citrate in subacute/remote HIT.
    • Bleeding: citrate; no anticoagulation only if unavoidable (pre-dilution, higher QB).
    Memory hook

    “Over 2.5, citrate is piling up. Under 2.5 with alkalosis, too much buffer.”

    Exam trap

    Calling accumulation an alkalosis. It is anion-gap acidosis, ratio >2.5. No shared ACT target.

  5. 5

    Stop 5 · Troubleshooting

    Filtration fraction and circuit troubleshooting

    High FF: haemoconcentration, protein deposition, circuit clotting.

    FF 35–40% keep <20–25%
    FFfraction= Total UFreplacement + net UF÷ Plasma flowQB × (1 − Hct)

    Dialysate not counted. Keep FF <20–25% (<20% if no anticoagulation).

    Worked example

    QB 200, Hct 0.30 → plasma flow 140 mL/min; UF 25 mL/min → FF ≈ 18%.

    Limitation: ignores pre-filter replacement.

    1. 1 · Increase blood flow

      Lowers FF; adjust citrate to the new QB.

    2. 2 · Pre-dilution

      Shift replacement fluid pre-filter.

    3. 3 · Optimise anticoagulation

      Post-filter iCa above target: citrate too low. Clotted: stop, change circuit, check coagulation.

    Circuit pressures

    • Rising pre-filter + TMP / pressure dropFilter clotting or fouling.
    • Very negative access pressureCatheter position, kinking or poor flow.
    • High return pressureClotted return lumen or kinked line.
    • Blood-leak alarmMembrane rupture: change the circuit at once.
    Emergency

    K still high on CRRT (e.g. 7.4): ECG, repeat K, IV calcium for ECG changes, temporising therapy; check circuit and flows; raise dialysate flow. No sustained dose escalation.

    Memory hook

    “Faster blood, dilute before, check the anticoagulant.”

  6. 6

    Stop 6 · Monitoring

    Drug dosing, electrolytes and nutrition

    Antibiotics, phosphate, magnesium and amino acids leave in effluent.

    full 1st dose q6h K · PO4 · Mg
    Antibiotics Full first dose
    Full, short infusion; maintenance by residual kidney + machine clearance.
    TDM: beta-lactams, vancomycin, aminoglycosides.
    Electrolytes K, PO4, Mg every 6 h
    Hypophosphataemia >50% (up to 65%): phosphate solution (~1 mmol/L) or supplement.
    Nutrition Amino acids leak
    0.2 g/L effluent → protein 1.2–1.5 g/kg/day (1.7 if hypercatabolic).
    Daily checks The rest of the board
    ABG, Hct (FF), aPTT if heparin, fluid balance, delivered dose, cultures.
    Red flags

    Severe hypotension, bradycardia, bleeding: stop and reassess. Air embolism, hypothermia. Antibiotic under-dosing.

  7. 7

    Stop 7 · Recovery

    Discontinuation

    Overload corrected, urine recovering, no new indication: trial off.

    >500 mL/day trial off
    Accepted criteria
    Urine >500 mL/day without diuretics, or ~2.4 L/day with.
    ICU guideline 2026
    Urine 300–600 mL/day without diuretics; K >5.5 or pH <7.3 predict failure.
    KDIGO 2026 draft
    >450 (no diuretics) or >2300 mL/24 h (diuretics) + 2-h CrCl ≥23 mL/min: predictors, not a rule.
    Exam trap

    Falling creatinine on active CRRT is not recovery.

    Memory hook

    “Dry first, urine back, no new reason: trial off.”

Pocket check

Rapid recall

What starts CRRT now in this patient?

Therapy-resistant K >6.0. Acidosis alone (pH <7.20) gets IV bicarbonate first.

Why CVVHDF, and why continuous?

Unstable → continuous; hyperkalaemia → diffusion, high dialysate flow.

Dose for a 100 kg patient?

Prescribe 25–30 mL/kg/h (~3,000 mL/h) to deliver 20–25; QB 150–200 mL/min.

What makes up the effluent?

Dialysate + replacement + net UF.

The FF equation and target?

FF = total UF ÷ plasma flow; plasma flow = QB × (1 − Hct). Keep <20–25%.

FF 35–40%, filter clotting?

Raise QB, shift replacement pre-filter, review anticoagulation. Clotted: hold, change circuit.

Citrate accumulation vs excess buffer?

Accumulation: ratio >2.5, anion-gap acidosis, rising Ca need. Excess buffer: alkalosis, ratio <2.5.

Dose and timing trials?

RENAL, ATN: more dose, no benefit. STARRT-AKI, AKIKI, IDEAL-ICU: earlier start, no benefit.

When do you trial off?

Overload corrected, urine >500 mL/day, no new indication.

Next tabs: detail, spoken answer, viva questions.

Sources: ICU RRT guideline 2026, KDIGO 2012 and 2026 draft, Clinical Handbook of Nephrology 2024.

📋

Case scenarios

Cases reported from real exam sittings.

Right IJ dual-lumen catheter; CVVHDF; dose 25-30 mL/kg/h (~3000 mL/h effluent prescribed, delivers ~2000-2500 mL/h, i.e. 20-25 mL/kg/h); QB 150-200; modest net UF per hemodynamics; split dialysate/replacement; regional citrate; full first antimicrobial dose, then maintenance for residual kidney plus CRRT clearance; monitor K/PO4/Mg q6h, post-filter and systemic ionized Ca per the citrate protocol.

FF = UF rate / plasma flow; plasma flow = QB x (1 - Hct).
Increase blood flow, move replacement to pre-filter (pre-dilution), ensure anticoagulation, keep FF <20-25%.
If clotted: stop, change circuit, recheck coagulation.

RENAL and ATN — higher dose (40/35 mL/kg/h) gives no benefit, so target 20-25 delivered.
STARRT-AKI/AKIKI — early initiation gives no mortality benefit.
Hemodiafe (2006): CVVHDF vs IHD, no 60-day survival difference; newer ICRAKI (2026): initial IHD not shown noninferior to CRRT, with higher mortality.

SCUF removes water only (no effective solute clearance). Hemofiltration (CVVH) uses convection to clear small and middle molecules with replacement fluid. CVVHD = diffusion (dialysate). CVVHDF = both.

Citrate accumulation (liver failure, shock, lactic acidosis): anion-gap acidosis, rising total calcium with low ionised calcium, total:ionised ratio above 2.5, escalating calcium need - stop citrate. Excess buffer: metabolic alkalosis with a ratio below 2.5. Also hypo- or hypercalcemia from wrong calcium dosing and hypernatremia with hypertonic citrate. Monitor post-filter and systemic ionized calcium per protocol (q6h once stable) and total calcium at least 12-hourly; the alternative is heparin, or argatroban in HIT.
🎓

Viva Q&A

Key points from this topic, framed as questions you could be asked in the viva.
tap to reveal · self-test
Q1Why CRRT rather than intermittent HD in this patient?reveal
Hemodynamic instability — CRRT removes fluid and solute slowly and is better tolerated; it is also preferred with raised ICP/brain injury and liver failure.
Q2Write your CRRT prescription.reveal
  • Right IJ dual-lumen access after consent
  • CVVHDF
  • dose 25-30 mL/kg/h (delivers ~20-25)
  • QB 150-200
  • modest net UF per hemodynamics
  • split dialysate/replacement (pre/post)
  • regional citrate anticoagulation
  • full first antimicrobial dose, then maintenance for residual kidney plus CRRT clearance
  • monitor K/PO4/Mg q6h, post-filter and systemic ionized Ca per the citrate protocol.
Q3What total effluent for a 100 kg patient?reveal
At ~30 mL/kg/h that is about 3000 mL/h; set net ultrafiltration first, then split the remainder between dialysate and replacement fluid. If BMI is 30 or more, the 2026 KDIGO draft suggests basing the initial dose on ideal or adjusted weight to avoid excess dose (PP 5.3.1).
Q4What is the ideal delivered dose and why not higher?reveal
20-25 mL/kg/h delivered — RENAL (40) and ATN (35) showed no benefit from higher intensity, so we prescribe 25-30 to reliably deliver 20-25.
Q5The nurse says the filtration fraction is 35% and the filter is clotting — what do you do?reveal
  • Increase blood flow
  • shift replacement to pre-filter (pre-dilution)
  • ensure adequate anticoagulation
  • and keep FF below 20-25%
If clotted, stop, change circuit, recheck coagulation.
Q6State the filtration fraction equation.reveal
FF = ultrafiltration rate / plasma flow rate, where plasma flow = blood flow x (1 - hematocrit).
Q7Which anticoagulation and what are its complications?reveal
Regional citrate is preferred; complications are citrate accumulation (anion-gap acidosis, total:ionised calcium above 2.5, rising calcium need), excess buffer (metabolic alkalosis with a ratio below 2.5), hypo- or hypercalcemia and hypernatremia with hypertonic citrate. Heparin is the alternative (protocols vary, for example 7-10 IU/kg/h in trial regimens, titrated to the local aPTT); argatroban in HIT.
Q8Difference between UF and hemofiltration, and the modes of CRRT?reveal
SCUF removes water only (no effective solute clearance); CVVH uses convection to clear small/middle molecules; CVVHD uses diffusion; CVVHDF combines both.
Q9Name a trial comparing CRRT with SLED/IHD and its result.reveal
Hemodiafe (Lancet 2006, 360 ICU patients with multi-organ failure) compared continuous haemodiafiltration with intermittent haemodialysis and found no difference in 60-day survival (about 33% with CVVHDF and 32% with IHD). ATN and RENAL tested dose, not modality. Newer: ICRAKI (NEJM 2026, stopped early) did not show initial IHD to be noninferior to CRRT for 90-day major adverse kidney events, with higher day-90 mortality (63.3% vs 53.6%, HR 1.30); it did not study SLED.
Q10Pre-dilution versus post-dilution — does it change clearance?reveal
Yes: pre-dilution dilutes the blood before the filter, so small-solute clearance per litre is lower and I prescribe a higher dose to compensate; in exchange pre-dilution reduces filter clotting, so it helps when the filtration fraction is high; it also lowers drug clearance by about 15% (KDIGO 2026 draft Table 34).
Q11K+ is still 7.4 after 6 hours — what now?reveal
Persistent K 7.4 on CRRT is an emergency. Call ICU/nephrology, get an ECG and continuous monitoring, send an urgent repeat potassium without delaying treatment, give IV calcium for hyperkalaemic ECG changes and repeat temporising therapy as indicated (insulin-dextrose, salbutamol), and follow potassium and glucose closely.
Check circuit patency, interruptions, delivered flows and the potassium in the solution, and raise diffusive clearance: a diffusive procedure with high dialysate flow is preferred in severe hyperkalaemia.
The routine dose remains 20-25 mL/kg/h delivered, because higher sustained doses (35-40 mL/kg/h) showed no survival benefit and more hypophosphataemia.
Q12When do you stop CRRT?reveal
Correct fluid overload first, reassess daily, and trial off when urine output recovers and there is no new indication: above 500 mL/day without diuretics or about 2.4 L/day with diuretics are widely accepted criteria from cohort studies (KDIGO 2026 draft PP 5.9.3: above 450 mL/24 h without diuretics or 2300 mL/24 h with diuretics, plus a 2-hour timed creatinine clearance of at least 23 mL/min, predicts successful discontinuation in adults; these are predictors, not a mandatory rule). A fall in creatinine on active CRRT alone does not show recovery; persistent K above 5.5 or pH below 7.3 predicts weaning failure; watch for recurrent hyperkalaemia, acidaemia and overload after stopping.
Q13Why exactly does a high filtration fraction cause filter clotting — what is the mechanism?reveal
High FF means too large a proportion of plasma water is removed across the filter membrane.
The blood remaining in the filter becomes haemoconcentrated: haematocrit rises, protein concentration rises, and viscosity increases.
Proteins deposit on the membrane surface (fouling), flow resistance increases, and the circuit clots.
Raising blood flow increases plasma flow and dilutes the concentrated blood; shifting replacement to pre-filter (pre-dilution) adds volume before the concentration rises — both act on the same root cause.
Q14On regional citrate the total calcium is rising but the ionised calcium stays low. What is it and what do you do?reveal
Citrate accumulation — citrate is not being metabolised (liver failure, shock, lactic acidosis), so citrate-calcium complexes build up: total calcium rises while ionised calcium stays low, the total:ionised calcium ratio climbs above 2.5, calcium requirements escalate and an anion-gap acidosis develops.
I treat the hypocalcemia, reduce the citrate rate and blood flow proportionally and raise the dialysate rate; if the ratio keeps rising or the calcium need escalates I stop citrate and switch to bicarbonate-buffered CRRT with heparin, or no anticoagulation if heparin is unsuitable (argatroban in HIT), with close laboratory follow-up.
Q15Could SLED be used instead of CRRT in an unstable ICU patient, and is there trial evidence?reveal
Yes, as prolonged intermittent therapy: slow diffusive clearance over a prolonged session (originally 6-8 hours overnight) give more haemodynamic stability than conventional HD, allow breaks for procedures or transport, and need less dedicated nursing.
The largest RCT (232 patients, SLED vs CVVH) found no difference in 90-day mortality (49.6% vs 55.6%), with shorter ventilation, ICU stay and time to recovery on SLED; it was single-centre and CVVH was run at about 31 mL/kg/h.
A meta-analysis of seven RCTs showed no mortality difference.
CRRT is preferred over conventional intermittent HD in raised ICP and in liver failure with encephalopathy, and there is no consensus on SLED dosing and frequency.
Q16Why can a pooled analysis of observational studies show lower mortality with SLED than CRRT, and can you trust it?reveal
Because SLED is probably chosen for the less sick patients; the randomised trials show no mortality difference, so the apparent advantage reflects selection bias.
Q17Which solutes and drugs does CRRT remove, and what does this mean for your orders?reveal
Phosphate, potassium and magnesium are cleared along with urea, so I replace phosphate (phosphate-containing fluid or supplement) and monitor K, Mg and phosphate 6-hourly.
Amino acids are lost at about 0.2 g/L of effluent, so protein is raised to 1.2-1.5 g/kg/day.
Drug removal by CRRT can match or exceed normal kidney clearance, so antimicrobials are dosed for CRRT rather than for anuria - under-dosing a septic patient is the usual error, though some agents need no adjustment.
Q18CVVH or CVVHDF - is one better, and what predicts successful weaning from CRRT?reveal
There is little outcome evidence to prefer one over the other, although the 2026 KDIGO draft favours CVVHD or CVVHDF over CVVH to prolong circuit life (PP 5.6.2); hemofiltration clears middle and larger molecules better but did not improve mortality in a meta-analysis, and CRRT versus intermittent HD shows no consensus on outcomes.
For weaning, rising urine output before cessation is the commonest predictor, together with improving kidney function tests, falling pressor needs and the patient's goals of care; I stop or switch to intermittent HD when these allow.
Q19On CRRT with regional citrate the patient becomes alkalotic. What is the mechanism and what do you adjust?reveal
Metabolised citrate generates bicarbonate, so the alkalosis comes from the citrate load plus the buffer in the circuit fluids (the same citrate that chelates calcium).
I lower the citrate dose or the buffer load of the replacement/dialysate fluid, re-check ionised calcium, and make sure total-to-ionised calcium is not climbing - a rising ratio or an anion-gap acidosis points to citrate accumulation, which needs the citrate dose cut and, if it keeps rising, citrate stopped and another anticoagulation used.
Q20If you chose SLED instead of CRRT, what would you prescribe?reveal
A typical SLED prescription is:
  • blood flow 150-300 mL/min
  • dialysate flow 100-300 mL/min
  • 6-12 hours per session
  • fluid removal under 500 mL/h
  • and 3-6 sessions a week, on a standard HD machine (or a CRRT machine).
It needs less anticoagulation than CRRT (for example pre-filter heparin 1000 U bolus then 500 U/h), corrects acidaemia faster, and the treatment-free periods allow transport and procedures so the clearance goal is more likely to be met.
Outcomes match CRRT (haemodynamic tolerance, recovery, mortality), so the choice rests on stability, bleeding risk and local resources; I still prefer CRRT for the most unstable patient or raised ICP.
Q21Why is intermittent HD risky in a uraemic patient with brain injury or raised ICP, and how do you reduce dialysis disequilibrium syndrome?reveal
Rapid urea removal leaves urea trapped in brain cells (reverse urea effect), so water moves into the brain and causes cerebral oedema; DDS ranges from nausea and cramps to encephalopathy, seizures, coma and herniation.
Risk is highest with a very high pre-dialysis urea, a first session or a large urea drop.
To reduce it:
  • smaller dialyzer surface area
  • slow blood flow (about 50-200 mL/min) or CRRT
  • short sessions (about 2 hours) repeated more often
  • higher dialysate sodium (143-146) or sodium modelling
  • lower dialysate bicarbonate
  • mannitol in the second hour
  • cool dialysate (35 C)
  • and haemodynamic stability.
If encephalopathy develops, stop dialysis, protect the airway, give hypertonic saline or mannitol, and image the brain; severe cases need CRRT.
Q22An ICU patient with septic AKI needs CRRT but the potassium is normal or low (for example 3.8). What changes in your prescription?reveal
The modality and dose stay the same (CVVHDF, 25-30 mL/kg/h), but the fluid must not be potassium-free.
A 4 mmol/L potassium solution usually keeps potassium normal on CKRT; lower concentrations are for starting a hyperkalaemic patient or when cells are breaking down (rhabdomyolysis), and a 0 mmol/L solution is hardly ever justified.
I check potassium, phosphate and magnesium every 6 hours, because CKRT removes them and most fluids lack phosphate, so I supplement phosphate after the first days and replete magnesium.
Q23An ICU patient with AKI has a bicarbonate of 5 and a CVP of 25. How do you adjust the CRRT prescription?reveal
For the acidosis I use bicarbonate-buffered fluids, which are now preferred for acid-base control and haemodynamic stability (bicarbonate about 32-35 mmol/L in the fluid, or 22-25 mmol/L if I use citrate).
With a severe acidosis and possible lactic acidosis or liver dysfunction I am careful with citrate and watch the total-to-ionised calcium ratio; a ratio above 2.5 means accumulation.
A CVP of 25 suggests venous congestion, so I confirm the CVP units and waveform and check cumulative balance, examination, bedside imaging and perfusion; if overload is present I set an individualised net ultrafiltration goal to remove fluid at the rate the blood pressure tolerates, reassessing hourly, and I protect the circuit against a high filtration fraction by raising blood flow and using pre-dilution.
I recheck pH and bicarbonate within hours.
Q24Which factors decide drug dosing in a septic patient on CRRT (KDIGO 2026 draft Table 34)?reveal
Drug: renally eliminated drugs with volume of distribution below 0.7 L/kg and/or protein binding below 80% are likely removed and may need supplemental doses; monitor levels for vancomycin, aminoglycosides, digoxin and calcineurin inhibitors.
Patient: sepsis, fluid resuscitation and capillary leak enlarge the volume of distribution, so the loading dose may be about 25% higher; hypoalbuminaemia raises the free fraction; with significant urine output (above 20 mL/h or 500 mL/day) the clearance from the residual urine volume is estimated and added to the CRRT clearance.
CRRT: clearance rises with the effluent rate and falls with downtime; CVVHDF clears more than CVVH, and pre-dilution lowers drug clearance by about 15%; if CRRT is under 25% of the patient's total clearance it adds little.
I dose by these factors, not by anuria alone (PP 4.5.4).
🗣

Spoken approach

say this aloud
🧠 Self-test — say each step from its label, then tap it to check.
  1. Opening: This is a 100 kg septic, anuric patient with potassium 7, severe acidosis and inotropes, and I manage it along the 2026 multidisciplinary ICU renal replacement guideline: start, mode, continuity, anticoagulation, dose, drugs, stopping.
  2. Stabilise: Therapy-resistant hyperkalaemia above 6.0 is an indication (acidosis alone below pH 7.2 gets IV bicarbonate first), so I start immediately, giving calcium, insulin with dextrose and salbutamol in parallel while access is placed.
  3. Treatment — access: After consent I place a non-tunnelled dual-lumen catheter, right internal jugular first choice, under ultrasound guidance, with a chest film before use.
  4. Treatment — mode and continuity: For severe hyperkalaemia I prefer a diffusive component with high dialysate flow, so CVVHDF. She is unstable, so I prefer continuous over intermittent to reduce hypotension.
  5. Treatment — anticoagulation: I choose regional citrate for longer filter life and less bleeding, monitoring post-filter and systemic ionised calcium, total calcium, acid-base and lactate. If it accumulates (total:ionised ratio above 2.5, rising calcium need, anion-gap acidosis) I stop citrate and switch to heparin or none, with bicarbonate; argatroban in acute HIT.
  6. Treatment — dose: I prescribe 25-30 mL/kg/h to deliver 20-25, about 2500-3000 mL/h for 100 kg, with bicarbonate buffer. For routine treatment I go no higher: ATN at 35 and RENAL at 40 showed no benefit, and no high-volume haemofiltration in sepsis.
  7. Follow-up — drugs and monitoring: The first antibiotic dose is full and a short infusion; maintenance follows residual kidney plus machine clearance (effluent rate, pre-dilution, downtime), with drug monitoring for beta-lactams, vancomycin and aminoglycosides. I check potassium, phosphate and magnesium 6-hourly.
  8. If it fails: If the filter clots I calculate FF = UF rate / plasma flow, plasma flow = QB x (1 - Hct), and keep it below 20-25%. I raise blood flow, shift replacement pre-filter, and review anticoagulation. If potassium stays dangerously high, for example 7.4 on treatment, it is an emergency: ECG and monitor, repeat potassium, IV calcium for ECG changes and repeat temporising therapy, check the circuit is running and the delivered flows, and raise diffusive clearance with high dialysate flow.
  9. Follow-up — stopping: I correct overload first and reassess daily, and I trial off when urine output recovers and there is no new indication: above 500 mL/day without diuretics or about 2.4 L/day with diuretics are accepted criteria; KDIGO 2026 draft PP 5.9.3 quotes above 450 or 2300 mL/24 h plus a 2-hour creatinine clearance of at least 23 mL/min as predictors of success, not a mandatory rule. A falling creatinine on active CRRT alone is not recovery.
⤴

Escalation ladder

and if that fails?

Prescribe: CVVHDF, 25-30 mL/kg/h, QB 150-200, modest net UF, citrate/heparin, q6h monitoring.

Nurse: FF 35-40%, filter clotting → increase blood flow → shift replacement to pre-filter → check/increase anticoagulation → keep FF <20-25%. If already clotted: hold CRRT, change the circuit, recheck coagulation.

Persisting hyperkalemia (for example K 7.4) or acidosis → emergency: ECG and monitor, repeat potassium, IV calcium for ECG changes, repeat temporising therapy, check access, circuit and delivered flows, and raise diffusive clearance with high dialysate flow (Rec 2.4); routine escalation of the dose to 35-40 mL/kg/h gave no survival benefit and more hypophosphataemia (Rec 5.1). Bleeding / high bleeding risk → regional citrate is preferred (Rec 4.2); anticoagulation-free is generally regarded as inferior, so use it only if unavoidable (pre-dilution with higher QB). HIT → argatroban. Recovery (urine output up, no new indication) → reassess daily and trial off CRRT.

💊

Management

Write the full prescription
Access, modality, dose
  • Access: dual-lumen catheter, right IJ, after consent
  • Modality: CVVHDF (anuric, needs UF + acidosis/hyperkalemia correction)
  • Dose: prescribe 25-30 mL/kg/h to deliver ~20-25; 100 kg -> ~2500-3000 mL/h effluent
  • Blood flow QB 150-200 mL/min
  • Dose arithmetic: effluent rate = dialysate flow + replacement flow + net ultrafiltration; dose (mL/kg/h) = effluent volume over 24 h / body weight / 24 (actual weight; for BMI ≥30 kg/m2 the 2026 KDIGO draft suggests ideal or adjusted weight, PP 5.3.1) - so a 75 kg patient needs 1,500-1,875 mL/h delivered; prescribe nearer 30 mL/kg/h (about 2,250 mL/h) because delivered dose falls below prescribed with filter clotting, procedures and transport. Check the delivered dose daily; if it is consistently below target (e.g. 18 against 25) fix the anticoagulation/circuit life first, then raise the prescribed rate. For 100 kg: 30 mL/kg/h = 3,000 mL/h prescribed; if the machine runs 20 h/day that is 60 L/day = 25 mL/kg/h averaged over 24 h, so estimate the real delivered dose instead of assuming it
Fluids, anticoagulation, monitoring
  • Net UF modest and individualised to hemodynamics (KDIGO 2026 draft PP 5.8.2): 1.01-1.75 mL/kg/h appeared safe in the ATN and RENAL secondary analyses, and rates above about 1.75 mL/kg/h were linked to higher mortality (an observational signal, not a fixed limit); split remainder dialysate/replacement (pre/post)
  • Anticoagulation: regional citrate (recommended over heparin when there is no contraindication, KDIGO 2026 draft Rec 5.5.1, 1B) or heparin (protocols vary: for example 7-10 IU/kg/h in trial regimens, titrated to the local aPTT target; UFH preferred over LMWH); argatroban in acute HIT
  • Full first antimicrobial dose, then maintenance for residual kidney plus CRRT clearance; give phosphate/magnesium replacement as needed
  • Monitor K/PO4/Mg q6h; with citrate, post-filter and systemic ionized Ca, total Ca and acid-base (see the citrate numbers below); APTT q6h if heparin (RICH target 45-60 s)
  • Citrate set-up numbers (mind the units): citrate runs pre-filter at a fixed ratio to blood flow, and the ratio must be written in matching units. With ACD-A (113 mmol/L citrate) a common fixed rate is citrate in mL/h = about 1.5 x QB in mL/min: QB 150 mL/min (= 9,000 mL/h of blood) takes 225 mL/h of ACD-A, which is only about 2.5% of blood flow in matching units, about 25 mmol citrate/h or about 2.8 mmol per litre of blood. Published fixed-rate tables for a blood citrate of 3 mmol/L give ACD-A 159 mL/h at QB 100, 239 mL/h at QB 150 and 319 mL/h at QB 200 (3-4 mmol/L is the usual target). Never apply 150% to blood flow expressed in mL/h: that would be about 13,500 mL/h, sixty times too much. When blood flow changes, change the citrate rate in proportion so the ratio stays the same. Give calcium separately to replace the calcium lost in the effluent and titrate it to the systemic ionised Ca (Clinical Handbook example: calcium gluconate 20 g in 500 mL D5W at 30 mL/h, increased if iCa is below 1.0 and decreased if above 1.1 mmol/L); common starting rules of thumb are 10% calcium gluconate at effluent mL/h ÷ 125 or 5% calcium chloride at effluent mL/h ÷ 200 (about 5 mmol/h at 3 L/h of effluent), always confirmed against the unit's validated citrate protocol. Monitoring: post-filter iCa to titrate the citrate dose when it is not fixed to blood flow (target below 0.35 mmol/L), systemic iCa to titrate calcium, iCa every 4 h initially then 6-hourly, and total calcium at least 12-hourly with the total:ionised ratio and acid-base to catch citrate accumulation (ratio above 2.5). Do not use a shared post-filter ACT target: citrate is titrated to post-filter iCa and heparin to aPTT or anti-Xa. Dialysate and replacement fluids are usually calcium-free with citrate, although calcium-containing fluids have been used with an adjusted calcium and citrate regimen, so use the fluids your validated protocol specifies
  • Anticoagulation targets: on regional citrate aim for a post-filter (circuit) ionised calcium below about 0.35 mmol/L (circuit citrate 3-5 mmol/L) while keeping the systemic ionised calcium in the normal range with the calcium infusion; if the circuit clots early, a post-filter iCa above target means the citrate dose is too low (note that raising blood flow dilutes circuit citrate, so adjust the citrate to the new blood flow). On heparin, typical protocols target a systemic aPTT of 45-60 s (RICH) (or anti-Xa 0.3-0.6 IU/mL)
Filtration fraction and troubleshooting
The FF equation (learn it exactly)
  • FF = UF rate / plasma flow rate (UF rate here = total ultrafiltrate, that is net UF plus the replacement fluid, in the same units as plasma flow; dialysate is not counted)
  • Plasma flow = blood flow (QB) x (1 - hematocrit)
  • Keep FF <20-25% (<20% if no anticoagulation) to reduce hemoconcentration and clotting
  • Worked example: QB 200 mL/min, Hct 0.30 -> plasma flow 140 mL/min (8,400 mL/h); a total ultrafiltrate of 1,500 mL/h (25 mL/min) gives FF = 25/140 = ~18%
  • Mechanism of high-FF clotting: when too high a fraction of plasma water is removed across the filter, the blood remaining in the filter becomes haemoconcentrated; rising haematocrit and protein concentration increase viscosity, proteins deposit on the membrane surface, and the circuit clots — this is why raising blood flow and shifting to pre-dilution are the two fastest corrective levers
  • Limitation of FF: it ignores pre-filter replacement fluid, so it is an imperfect index of clotting risk; end-of-filter haematocrit is an alternative index but is not yet validated. Experts quote keeping FF below 20-30%
High FF / clotting filter — actions
  • Increase blood flow rate (raises plasma flow, lowers FF)
  • Increase pre-filter (pre-dilution) replacement fluid
  • Optimise/ensure anticoagulation (citrate or heparin)
  • Reduce net ultrafiltration (debated); if clotted, stop, change circuit, check coagulation
  • Read the CRRT pressures before touching the prescription:
    • rising pre-filter pressure with a rising transmembrane pressure/pressure drop = filter clotting or membrane fouling and an imminent circuit change
    • a very negative access (inflow) pressure = catheter position/kinking or poor flow
    • high return (venous) pressure = clotted return lumen or kinked line
    • a blood-leak alarm = membrane rupture, change the circuit at once
Pharmacology
ItemSettingValue / note
Dose (effluent)Prescribed25-30 mL/kg/h (delivers ~20-25); 100 kg ~3000 mL/h
Blood flow (QB)Pump150-200 mL/min
Net ultrafiltrationVolume removalModest and individualised; 1.01-1.75 mL/kg/h appeared safe, above about 1.75 linked to worse survival (observational)
Regional citrateAnticoagulation (preferred)Citrate rate fixed to blood flow (ACD-A mL/h = about 1.5 x QB mL/min); watch hypocalcemia, alkalosis (excess buffer), accumulation (total:ionised Ca above 2.5, anion-gap acidosis), hypernatremia with hypertonic citrate
HeparinAnticoagulation (alt)Protocols vary (trial example: bolus 2,000-5,000 IU, then 7-10 IU/kg/h); titrate to local aPTT (RICH 45-60 s), APTT q6h
ArgatrobanAnticoagulation in HITDirect thrombin inhibitor
⚡

Quick reference

numbers at a glance
When CRRTUnstable, raised ICP, liver failure
ModalityCVVHDF (anuric + acidosis + hyperkalemia)
Dose25-30 mL/kg/h (deliver 20-25); 100 kg ~3000 mL/h
Blood flowQB 150-200 mL/min
FF equationFF = UF rate / plasma flow; plasma flow = QB x (1 - Hct); keep <20-25%
High FF / clottingRaise QB, pre-filter replacement, anticoagulate
AnticoagCitrate (monitor iCa; total:ionised Ca above 2.5 = accumulation, stop citrate) or heparin; argatroban in HIT
TrialsRENAL, ATN (dose), STARRT-AKI (timing)
⚑

Red flags

must not miss
  • Filtration fraction >20-25% — haemoconcentration and shorter filter life; act early (raise QB, pre-dilution, review anticoagulation)
  • Citrate accumulation (toxicity) — rising total:ionised calcium ratio above 2.5, low systemic ionised calcium with rising calcium need, anion-gap metabolic acidosis (raised lactate, shock and liver failure are the risk factors): treat the hypocalcemia and stop citrate, switching to bicarbonate-buffered CRRT with heparin or no anticoagulation; metabolic alkalosis with a ratio below 2.5 is excess buffer, a different problem, and hypernatremia comes with hypertonic citrate; avoid citrate with progressive lactic acidosis plus shock and severe liver failure
  • Severe hypotension/bradycardia or active bleeding on CRRT — stop and reassess
  • Air embolism, hypothermia, hypophosphatemia/hypomagnesemia — known CRRT complications
  • Under-dosing antibiotics on CRRT — give a full first dose, then dose maintenance for residual kidney plus CRRT clearance
  • CRRT electrolyte and nutrient losses: hypophosphataemia occurs in more than 50% of CKRT patients (up to 65% at high effluent rates) and nearly doubles prolonged respiratory failure - use a phosphate-containing solution (about 1 mmol/L) or supplement phosphate, and watch potassium and magnesium; amino acids are lost at about 0.2 g per litre of effluent, so protein intake on KRT is 1.2-1.5 g/kg/day (up to 1.7 in hypercatabolism)
🧭

Flowchart

memorize this
graph TD;
A["Septic AKI, unstable, anuric, K7, acidosis"] --> B{"Hemodynamically unstable or raised ICP or liver failure?"};
B -->|Yes| C["Choose CRRT (CVVHDF)"];
B -->|No| D["Consider IRRT or SLED"];
C --> E["Access right IJ, dose 25-30 mL/kg/h, QB 150-200"];
E --> F["Set modest net UF, split dialysate and replacement"];
F --> G["Anticoagulate: citrate preferred or heparin"];
G --> H{"Filter clotting or FF over 20-25%?"};
H -->|Yes| I["Raise blood flow, pre-filter replacement, ensure anticoagulation"];
H -->|No| J["Monitor K, PO4, Mg q6h and ionized Ca per citrate protocol"];
I --> J;
J --> K{"Recovery, urine output rising and no new indication?"};
K -->|Yes| L["Trial off CRRT and reassess daily"];
K -->|No| M["Continue, if K stays dangerously high it is an emergency, ECG, repeat K, IV calcium, check circuit and delivered flows, raise dialysate flow"];
◈

Exam traps & pitfalls

where marks are lost
  • Not knowing the filtration fraction equation — the examiner's favourite trap
  • Quoting 35-40 mL/kg/h as the target dose (that is the RENAL/ATN arm that failed) instead of 20-25 delivered
  • Choosing IRRT for a patient on maximal inotropes
  • Forgetting to monitor ionized calcium on citrate, and calling accumulation alkalosis (accumulation = anion-gap acidosis with total:ionised calcium above 2.5; alkalosis with a ratio below 2.5 is excess buffer)
  • Setting aggressive net ultrafiltration in a shocked patient
  • Omitting drug dose adjustment for CRRT clearance
🔬

Differential

Modality choice (unstable patient)
  • CRRT — hemodynamic instability, raised ICP/brain injury, liver failure, on high inotropes (2026 KDIGO draft: CRRT or acute PD over conventional IRRT, Rec 5.2.1, 2C)
  • IRRT (intermittent HD) — stable patient needing rapid removal (severe hyperkalemia, urgent overload)
  • SLED / prolonged intermittent — hybrid (PIRRT); an acceptable alternative to CRRT in unstable patients (2026 KDIGO draft PP 5.2.4)
CRRT modalities (know the mechanism)
  • SCUF — water removal only (no effective solute clearance)
  • CVVH — convection (good for small + middle molecules); needs replacement fluid
  • CVVHD — diffusion (small solutes); uses dialysate
  • CVVHDF — diffusion + convection combined (typical ICU choice)
Anticoagulation options
  • Regional citrate — preferred; complications: excess buffer (metabolic alkalosis with total:ionised Ca below 2.5), citrate accumulation (anion-gap acidosis, total:ionised Ca above 2.5, rising calcium need), hypo- or hypercalcemia, hypernatremia with hypertonic citrate, hypomagnesemia
  • Unfractionated heparin — protocols vary widely (trial regimens: bolus about 2,000-5,000 IU, then about 7-10 IU/kg/h; a lower typical order is 500-1,000 IU then about 500 IU/h); titrate to the local aPTT target (RICH 45-60 s)
  • Argatroban (or bivalirudin, danaparoid) — alternative in acute HIT needing systemic anticoagulation; citrate preferred in subacute or remote HIT (2026 KDIGO draft PP 5.5.4-5.5.5); no anticoagulation option if bleeding (pre-dilution + higher QB)
🔑

Examiner keywords

the words he waits for
hemodynamically unstable = CRRTthe indication over intermittent HDCVVHDFmodality for anuric patient needing UF plus acidosis correction25-30 mL/kg/hprescribed dose to deliver ~20-25 effluent100 kg = ~3000 mL/h effluentthe worked dose numberQB 150-200blood flow settingFF = UF rate / plasma flowthe equation the examiner waits forplasma flow = QB x (1Hct) — completes the FF calculationkeep FF <20-25%threshold to avoid filter clottingregional citratepreferred anticoagulation, watch ionised calcium, the total:ionised ratio (above 2.5 = accumulation) and acid-baseRENAL / ATN / STARRT-AKIdose and timing trials, no benefit from more/earlier
🔎

Investigations & data

  • ABG/VBG — degree of acidosis, guides bicarbonate/citrate buffering
  • Serum K, PO4, Mg, ionized calcium — baseline and q6h on CRRT
  • Hematocrit — needed to compute plasma flow and filtration fraction
  • Coagulation (APTT) — baseline and monitoring if heparin
  • Fluid balance/CVP and hemodynamics — set net ultrafiltration target
  • Cultures/source workup for the underlying sepsis
Reading the data
ScenarioAction
100 kg, dose 30 mL/kg/hTotal effluent ~3000 mL/h prescribed; set net UF then split dialysate/replacement; running 20 h/day gives 60 L/day = 25 mL/kg/h averaged over 24 h
Nurse: filtration fraction 35-40%, filter clottingIncrease blood flow, shift replacement to pre-filter, ensure/optimise anticoagulation, keep FF <20-25%
On citrate: metabolic alkalosis, total:ionised Ca below 2.5Excess buffer — review the buffer in the fluids and the citrate rate (proportional to blood flow); titrate calcium to the systemic ionised Ca
On citrate: anion-gap acidosis, total:ionised Ca above 2.5, rising calcium need, low systemic ionised CaCitrate accumulation — treat the hypocalcemia; reduce the citrate rate, and if it persists stop citrate (bicarbonate-buffered CRRT with heparin or no anticoagulation)
Refractory hyperkalemia/acidosis persistsEmergency if potassium stays dangerously high (for example 7.4): ECG and monitor, repeat potassium, IV calcium for ECG changes, repeat temporising therapy; check access, circuit and delivered flows and raise diffusive clearance (high dialysate flow). The routine dose stays 20-25 mL/kg/h delivered, with no sustained escalation (2026 KDIGO draft Rec 5.3.1, 1B)
Urine output recoversReassess daily and trial off CRRT if no new indication; a falling creatinine on active CRRT alone does not show recovery
📐

Guideline algorithm

the source this answer follows

Source: Multidisciplinary guidelines on renal replacement therapy in intensive care medicine, Critical Care 2026 (German/Austrian 12-society consensus, accepted Dec 2025); numbered recommendations are from this guideline, and rows marked KDIGO 2012, KDIGO 2026 draft or Clinical Handbook of Nephrology 2024 are separate adjuncts. KDIGO 2026 AKI/AKD is still a draft.

#StepGuideline content
1StartImmediately for life-threatening fluid, acid-base or electrolyte change (K >6.0, pH <7.2, overload, uraemia; therapy-resistant) (Rec 1.1). KDIGO 2026 draft: deferred rather than early start (Rec 5.1.1, 1C); start for medically refractory complications if consistent with goals of care (PP 5.1.3); pH <7.20 alone, IV bicarbonate over RRT unless another urgent indication (Rec 3.1.3, 2C).
2Access (KDIGO 2012)Non-tunnelled catheter; right jugular first choice; ultrasound guidance; chest film before use of IJ or subclavian (5.4.1-5.4.4).
3Diffusion / convectionSimilar outcomes (2.1); pre-dilution may be preferred with repeated clotting (2.2); severe hyperkalaemia: diffusive with high dialysate flow (2.4). Hence CVVHDF.
4Continuous vs intermittentEqual for survival in older trials (3.1; the newer ICRAKI trial, NEJM 2026, did not show initial IHD to be noninferior to CRRT and found higher mortality); unstable patients: continuous or prolonged to reduce hypotension (3.3).
5AnticoagulationCitrate = heparin for outcomes (4.1); citrate if bleeding risk or heparin shortens filters (4.2-4.3); shock/liver failure not absolute contraindications, monitor lactate, ionised and total calcium (4.4); accumulation: heparin or none with bicarbonate buffer (4.5); avoid with progressive lactic acidosis, shock and severe liver failure (4.6); UFH over LMWH (4.7); HIT: argatroban (4.8). KDIGO 2026 draft instead recommends citrate over heparin for CRRT (Rec 5.5.1, 1B), with UFH, epoprostenol or nafamostat as alternatives (PP 5.5.1); acute HIT: argatroban, danaparoid or bivalirudin (PP 5.5.4).
6Dose20-25 mL/kg/h (5.1, A); prescribe about 25-30 to deliver it; no high-volume haemofiltration in sepsis (5.4). Blood flow 100-250 mL/min (CHN 2024 p170); bicarbonate buffer in shock (KDIGO 5.7.2). KDIGO 2026 draft agrees: 20-25 mL/kg/h (Rec 5.3.1, 1B), no HVHF in sepsis (Rec 5.3.2, 1B), bicarbonate rather than lactate in shock, liver failure or lactic acidaemia (PP 5.7.1).
7DrugsFirst dose full and short infusion (6.1-6.3); maintenance by total clearance incl. machine (6.4); TDM for beta-lactams, vancomycin, aminoglycosides (6.8). KDIGO 2026 draft PP 4.5.4: adjust dosing by drug-, patient- and RRT-related factors (Table 34).
8Troubleshooting (CHN 2024 p171)FF = UF rate / plasma flow, plasma flow = BFR x (1 - Hct), UF rate = total ultrafiltrate (net UF plus replacement fluid, dialysate not counted); experts keep FF below 20-30%.
9StoppingCorrect overload first (7.8); urine output 300-600 mL/day without diuretics as guidance (7.3), the KDIGO 2026 draft PP 5.9.3 gives >450 mL/24 h without diuretics or >2300 mL/24 h with diuretics plus 2-h creatinine clearance ≥23 mL/min as predictors of successful discontinuation, not a mandatory rule; K >5.5 or pH <7.3 predict weaning failure (7.5, 7.7).

Alternative: KDIGO 2012 section 5 suggests regional citrate rather than heparin (2B), CRRT for unstable patients (2B), and delivered 20-25 mL/kg/h (1A, prescribe higher). KDIGO 2026 draft (March 2026, not final) recommends citrate over heparin (1B), suggests CRRT or acute PD for unstable patients (2C) and effluent 20-25 mL/kg/h (1B).

🆕

Recent changes

what changed — say it
  • Label as draft: the 2026 KDIGO draft upgrades citrate for CRRT to a 1B recommendation and favours a deferred start; until it is final, KDIGO 2012 is the published standard.
    DRAFT (March 2026, not final): KDIGO 2026 AKI/AKD recommends regional citrate rather than heparin for CRRT when there is no contraindication (Rec 5.5.1, 1B; KDIGO 2012 Rec 5.3.2.2 only suggested it, 2B), a deferred rather than early (pre-emptive) RRT start (Rec 5.1.1, 1C), and CRRT or acute PD over conventional intermittent RRT in haemodynamically unstable adults (Rec 5.2.1, 2C).
    KDIGO 2026 draft
⚡

Immediate priorities

ordered
  • Confirm CRRT is indicated: hemodynamic instability, refractory hyperkalemia, severe metabolic acidosis not corrected by IV bicarbonate (pH below 7.20 alone: bicarbonate first, KDIGO 2026 draft Rec 3.1.3), anuria/fluid overload.
  • Treat life-threatening hyperkalemia medically in parallel (calcium, insulin-dextrose, salbutamol) while setting up; if potassium stays dangerously high on CRRT (for example 7.4) treat it as an emergency: ECG and monitor, repeat potassium, repeat temporising therapy, check the circuit and delivered flows, raise diffusive clearance.
  • Secure vascular access (dual-lumen catheter, right IJ) after consent.
  • Choose CVVHDF for the anuric patient needing UF + solute/acidosis correction.
  • Prescribe dose 25-30 mL/kg/h (delivered ~20-25); QB 150-200 mL/min.
  • Set modest net UF guided by hemodynamics; split remainder dialysate/replacement.
  • Start anticoagulation (KDIGO 2026 draft recommends regional citrate over heparin if no contraindication (Rec 5.5.1, 1B); heparin if citrate is contraindicated or unavailable; monitor lactate, ionised and total calcium on citrate).
  • Give the full first antimicrobial dose, then dose maintenance for residual kidney plus CRRT clearance; monitor K/PO4/Mg q6h, post-filter and systemic ionized Ca per the citrate protocol, APTT q6h (heparin, per local protocol).
🧬

Why it happens

the mechanism behind the plan
  • Continuous, slow solute and fluid removal avoids rapid osmotic and volume shifts → CRRT suits shocked patients on inotropes, and raised ICP or liver failure, over intermittent HD.
  • CVVHDF combines diffusion and convection with ultrafiltration → it clears potassium and acid and removes fluid in an anuric patient, which is why it is the modality chosen here.
  • Delivered dose falls below prescribed because of downtime → prescribe modestly above the target, but no higher, since RENAL and ATN showed no benefit from more.
  • Citrate chelates calcium to prevent clotting, and its metabolism generates bicarbonate → monitor ionised calcium and watch for alkalosis or accumulation.

📎 Related topics — deeper dives

In-depth references related to this exam case

Writing a CRRT Order: Modality, Fluids, Citrate and Alarm TroubleshootingCRRT versus SLED in the Unstable ICU PatientCRRT Effluent Dose in the ICU: KDIGO 20-25 mL/kg/h, RENAL and ATNCRRT Alarms, Citrate and Troubleshooting Scenarios
Practice & Recall
Reading Mode
Saved
🔖 My bookmarksBrowse all saved sections & notes
Share & Export

Your study progress

    Every section is studied.

    🎙️
    Podcast CRRT Prescription (Septic ICU)
    0:00 0:00
    Podcast
    Consultant Viva Simulator

    CRRT Prescription (Septic ICU)

    💡 Screen-Share Drill: With Gemini Live active, say: "Read my screen and examine me on this topic"
    EXAMINER BRIEF & MARKING SCHEME (22 CRITERIA) 🖥️ Screen-Share Ready
    ROLE
    You are examining me for the nephrology CONSULTANT viva. It is an oral exam on Zoom: two sittings, two examiners, about six questions each. One examiner is gentle; the second wants detail everywhere.
    
    WHAT IS ON MY SCREEN
    A study app. Each topic shows a numbered "Say this" model answer and an amber "examiner wants" list — those are the exact keywords real examiners listened for. Use that list as your marking scheme.
    
    RULES — follow these strictly
    1. Ask ONE question out loud, then STOP and wait. Do not speak again until I have finished answering.
    2. Never read the model answer or the keyword list aloud before I answer, and never hint. If I stall, say "take your time" — nothing else.
    3. Expect 60-90 seconds from me. Past two minutes, cut me off politely and move on, exactly as a real examiner would.
    4. When I stop, mark me: go through the on-screen keyword list and tell me which ones I actually said and which I missed. Quote the missed ones word for word.
    5. Then ask ONE follow-up — a "why", a dose, a trial name, a guideline year, or a twist to the case. This is where the real exam is won or lost.
    
    HOW TO MARK ME
    - Be strict and unsentimental. "Manage appropriately", "treat the underlying cause", "I would refer" are not answers — challenge them immediately.
    - A missing dose, threshold, trial name or guideline version is a lost mark. Say so out loud.
    - Never praise fluency that carries no content.
    - If I say something factually wrong, correct it on the spot, precisely, and tell me what the right figure is.
    - Do not soften your scoring to be encouraging. I need the real number.
    
    LANGUAGE — this matters, follow it exactly
    - Ask every question in ENGLISH. The real exam is in English and I need to practise hearing it that way.
    - I will answer in English, sometimes mixed with Arabic. Judge the medicine, not the language.
    - BUT when you MARK me — the score, what I missed, the feedback, the final summary — speak EGYPTIAN COLLOQUIAL ARABIC (عامية مصرية).
    - Inside that Arabic, keep every medical term, drug name, dose, trial name, guideline and threshold in ENGLISH. Never translate them into Arabic.
    - Give the score in this exact shape:
      "انت جبت ٥ من ١٠ علشان نسيت treatment of edema with diuretics، ونسيت تدي المريض statin، وماقلتش anti-PLA2R titre."
    - Then say, still in Egyptian Arabic, إيه اللي كان لازم تقوله بالظبط — with the English terms in place.
    
    AFTER EVERY MARK — always end your turn with this, in Egyptian Arabic, then STOP and wait:
      "تمام. نعدّي لسؤال تاني؟ ولا تحب نتناقش أكتر في السؤال ده؟ ولا عندك اعتراض على حاجة؟"
    Never move to the next question until I answer that.
    If I object to something you said: take it seriously and re-check your own claim before you defend it — I may well be right, and the guideline may have moved. If you were wrong, say so plainly and give me the correct figure. If I am the one who is wrong, do NOT back down to be polite: hold your position and tell me the evidence — the guideline, the trial, the number. Caving to a confident candidate is exactly how a wrong fact survives to the real exam.
    
    THIS SESSION
    Drill me on ONE topic only: CRRT Prescription (Septic ICU).
    The marking scheme for this topic is:
    1. hemodynamically unstable = CRRT — the indication over intermittent HD
    2. CVVHDF — modality for anuric patient needing UF plus acidosis correction
    3. 25-30 mL/kg/h — prescribed dose to deliver ~20-25 effluent
    4. 100 kg = ~3000 mL/h effluent — the worked dose number
    5. QB 150-200 — blood flow setting
    6. FF = UF rate / plasma flow — the equation the examiner waits for
    7. plasma flow = QB x (1 - Hct) — completes the FF calculation
    8. keep FF
    9. regional citrate — preferred anticoagulation, watch ionised calcium, the total:ionised ratio (above 2.5 = accumulation) and acid-base
    10. RENAL / ATN / STARRT-AKI — dose and timing trials, no benefit from more/earlier
    11. Red flag: Filtration fraction >20-25% — haemoconcentration and shorter filter life; act early (raise QB, pre-dilution, review anticoagulation)
    12. Red flag: Citrate accumulation (toxicity) — rising total:ionised calcium ratio above 2.5, low systemic ionised calcium with rising calcium need, anion-gap metabolic acidosis (raised lactate, shock and liver failure are the risk factors): treat the hypocalcemia and stop citrate, switching to bicarbonate-buffered CRRT with heparin or no anticoagulation; metabolic alkalosis with a ratio below 2.5 is excess buffer, a different problem, and hypernatremia comes with hypertonic citrate; avoid citrate with progressive lactic acidosis plus shock and severe liver failure
    13. Red flag: Severe hypotension/bradycardia or active bleeding on CRRT — stop and reassess
    14. Red flag: Air embolism, hypothermia, hypophosphatemia/hypomagnesemia — known CRRT complications
    15. Red flag: Under-dosing antibiotics on CRRT — give a full first dose, then dose maintenance for residual kidney plus CRRT clearance
    16. Red flag: CRRT electrolyte and nutrient losses: hypophosphataemia occurs in more than 50% of CKRT patients (up to 65% at high effluent rates) and nearly doubles prolonged respiratory failure - use a phosphate-containing solution (about 1 mmol/L) or supplement phosphate, and watch potassium and magnesium; amino acids are lost at about 0.2 g per litre of effluent, so protein intake on KRT is 1.2-1.5 g/kg/day (up to 1.7 in hypercatabolism)
    17. Exam trap: Not knowing the filtration fraction equation — the examiner's favourite trap
    18. Exam trap: Quoting 35-40 mL/kg/h as the target dose (that is the RENAL/ATN arm that failed) instead of 20-25 delivered
    19. Exam trap: Choosing IRRT for a patient on maximal inotropes
    20. Exam trap: Forgetting to monitor ionized calcium on citrate, and calling accumulation alkalosis (accumulation = anion-gap acidosis with total:ionised calcium above 2.5; alkalosis with a ratio below 2.5 is excess buffer)
    21. Exam trap: Setting aggressive net ultrafiltration in a shocked patient
    22. Exam trap: Omitting drug dose adjustment for CRRT clearance
    
    Ask me an opening case stem on this topic, mark me against that list, then escalate: doses, the trials by name, the pitfalls, and one "what if" twist to the case. Four to six exchanges.
    
    AT THE END, in Egyptian Arabic with the medical terms in English: قولّي أكتر حاجة ممكن تضيع مني درجات في الموضوع ده في الامتحان الحقيقي، وقول بصوت عالي نسخة الـ ٦٠ ثانية اللي كان المفروض أقولها.
    
    Begin when I say "ready".
    Consultant Viva · Egyptian Arabic Marking

    Report a mistake

    Please sign in to report a mistake, so we can ask you if we need more details.

    Sign in

    Liked this topic?

    Every exam case is built the same way. Subscribe to open all of them.

    See the plans →
    Home All Topics Contact Us Terms of Service Privacy Policy Refund Policy Facebook YouTube Monawib

    Tools: Nephrology tools · Radiology

    Disclaimer: NephroApp is an independent educational platform and is not affiliated with, endorsed by, or sponsored by any licensing authority, examination provider, or textbook publisher. The MCQ Bank provides exam-style practice for educational purposes.

    Nephroapp© 2026. All rights reserved.

    Made with by Dr. Hossam Abohassan